{"id":"influenza-vaccine-adjuvanted","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adjuvanted influenza vaccines contain an immunological adjuvant that amplifies the body's innate immune response to the vaccine antigens, leading to stronger and more durable antibody responses and T-cell activation. This approach is particularly beneficial in populations with weaker immune responses, such as elderly individuals. The adjuvant works by activating pattern recognition receptors and enhancing antigen presentation to immune cells.","oneSentence":"An adjuvanted influenza vaccine that enhances immune response through the addition of an adjuvant to improve antibody production and cellular immunity against influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:28.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT06417853","phase":"PHASE1","title":"Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)","status":"COMPLETED","sponsor":"Vaxxas Pty Ltd","startDate":"2024-07-31","conditions":"H7N9 Influenza","enrollment":267},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06676644","phase":"NA","title":"Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Influenza Vaccines, Elderly","enrollment":200},{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT07386509","phase":"EARLY_PHASE1","title":"WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-03-17","conditions":"Healthy","enrollment":2},{"nctId":"NCT06560151","phase":"PHASE2","title":"Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-08-21","conditions":"Influenza","enrollment":1380},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT02872311","phase":"NA","title":"Open-Label Influenza Vaccine Evaluation","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2016-09","conditions":"Immune Response","enrollment":179},{"nctId":"NCT01024400","phase":"PHASE2","title":"Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Influenza","enrollment":110},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT05608005","phase":"PHASE1, PHASE2","title":"Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-03","conditions":"Influenza, Healthy Volunteers","enrollment":581},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT06842173","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults","status":"RECRUITING","sponsor":"Butantan Institute","startDate":"2025-09-01","conditions":"Avian Influenza A Virus","enrollment":700},{"nctId":"NCT07126652","phase":"NA","title":"Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-10-01","conditions":"Antibody Response","enrollment":300},{"nctId":"NCT05291676","phase":"PHASE2","title":"Systems Investigation of Vaccine Responses in Aging and Frailty","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-11-06","conditions":"Influenza","enrollment":96},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06460064","phase":"PHASE1","title":"First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2024-06-26","conditions":"Influenza","enrollment":144},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT05110911","phase":"","title":"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-04-02","conditions":"Influenza, Human, SARS-CoV-2 Infection","enrollment":1500},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT05875961","phase":"PHASE1","title":"Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-15","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":600},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT05874713","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-07","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":480},{"nctId":"NCT02839330","phase":"PHASE3","title":"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-07-11","conditions":"Avian Influenza","enrollment":3196},{"nctId":"NCT02871206","phase":"PHASE4","title":"Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-11","conditions":"Influenza","enrollment":3425},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT03369808","phase":"PHASE1, PHASE2","title":"A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2017-12-29","conditions":"H7N9 Influenza","enrollment":360},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT03894969","phase":"PHASE2","title":"Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-23","conditions":"Respiratory Disorders","enrollment":541},{"nctId":"NCT05518500","phase":"PHASE4","title":"A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults","status":"RECRUITING","sponsor":"The Jackson Laboratory","startDate":"2022-08-31","conditions":"Aging, Influenza Vaccine, Dendritic Cell","enrollment":75},{"nctId":"NCT05397119","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2022-07-07","conditions":"Influenza, Pandemic","enrollment":40},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT03694808","phase":"PHASE4","title":"FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care","status":"COMPLETED","sponsor":"David H. Canaday","startDate":"2018-09-23","conditions":"Flu","enrollment":478},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT05781191","phase":"","title":"Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-13","conditions":"Influenza, COVID-19","enrollment":8231},{"nctId":"NCT04669691","phase":"PHASE2","title":"A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-12-19","conditions":"Influenza, Human","enrollment":420},{"nctId":"NCT06304038","phase":"","title":"Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2017-10-16","conditions":"Influenza Vaccine, Cost-Benefit Analysis","enrollment":5483},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279},{"nctId":"NCT05581407","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin","status":"COMPLETED","sponsor":"LiteVax BV","startDate":"2022-10-03","conditions":"Influenza","enrollment":60},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT02529904","phase":"PHASE2","title":"ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Influenza","enrollment":120},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT05422326","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-07-18","conditions":"Influenza, Human, Influenza in Birds, Respiratory Tract Infections","enrollment":260},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT03603509","phase":"PHASE4","title":"Gene Signatures of Influenza Vaccine Responses in Older Adults","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-08-27","conditions":"Influenza","enrollment":241},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT03599739","phase":"","title":"Adjuvanted Influenza Vaccination Year 2 Follow-On Survey","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2018-07-13","conditions":"Influenza, Influenza-like Illness, Influenza, Human","enrollment":598},{"nctId":"NCT02882100","phase":"PHASE4","title":"Adjuvanted Influenza Vaccination in U.S. Nursing Homes","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2016-04","conditions":"Influenza, Influenza-like Illness","enrollment":823},{"nctId":"NCT02255409","phase":"PHASE3","title":"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-10","conditions":"Influenza","enrollment":607},{"nctId":"NCT00877448","phase":"PHASE1, PHASE2","title":"A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2009-06","conditions":"Healthy","enrollment":63},{"nctId":"NCT01320696","phase":"PHASE1, PHASE2","title":"Reverse Genetic H9N2 Influenza Vaccine Study in Adults","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2011-03","conditions":"Influenza","enrollment":353},{"nctId":"NCT02523287","phase":"PHASE4","title":"Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-10-02","conditions":"Safety Markers of Adjuvanted Influenza Vaccine","enrollment":240},{"nctId":"NCT05035680","phase":"PHASE1","title":"Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion","status":"WITHDRAWN","sponsor":"Gates Medical Research Institute","startDate":"2022-07-14","conditions":"Influenza","enrollment":""},{"nctId":"NCT01012557","phase":"NA","title":"H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women","status":"COMPLETED","sponsor":"Copenhagen Studies on Asthma in Childhood","startDate":"2009-11","conditions":"H1N1v Influenza","enrollment":296},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT01310413","phase":"PHASE3","title":"Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-07","conditions":"Influenza, Influenza Vaccines","enrollment":842},{"nctId":"NCT00956111","phase":"PHASE4","title":"A Clinical Trial With Influenza A/H1N1 Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2009-07","conditions":"Influenza","enrollment":1614},{"nctId":"NCT03275389","phase":"PHASE1","title":"A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-08","conditions":"Influenza, Human","enrollment":470},{"nctId":"NCT00841763","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Pandemic Influenza Disease","enrollment":3647},{"nctId":"NCT01342796","phase":"PHASE2","title":"Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus","enrollment":84},{"nctId":"NCT03183908","phase":"PHASE4","title":"FLUAD® vs. Fluzone® High-Dose Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-28","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":757},{"nctId":"NCT04806529","phase":"PHASE2, PHASE3","title":"An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older","status":"WITHDRAWN","sponsor":"Seqirus","startDate":"2020-12-15","conditions":"Influenza","enrollment":""},{"nctId":"NCT02933723","phase":"NA","title":"Immunogenicity of Influenza Vaccine in Long Term Care","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2016-10","conditions":"Influenza","enrollment":200},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT01195779","phase":"PHASE2","title":"Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-09-30","conditions":"Influenza, Influenza Vaccines","enrollment":4},{"nctId":"NCT03330899","phase":"PHASE1","title":"Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2018-09-24","conditions":"Influenza, H7N9 Influenza","enrollment":432},{"nctId":"NCT02962908","phase":"PHASE2","title":"A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine","status":"COMPLETED","sponsor":"PepTcell Limited","startDate":"2016-08","conditions":"Influenza","enrollment":175},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT00812019","phase":"PHASE1","title":"Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-11","conditions":"Influenza","enrollment":753},{"nctId":"NCT03318315","phase":"PHASE2","title":"Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-02-20","conditions":"Avian Influenza, Influenza, Influenza Immunisation","enrollment":149},{"nctId":"NCT03180801","phase":"PHASE2","title":"Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model","status":"COMPLETED","sponsor":"PepTcell Limited","startDate":"2016-08-18","conditions":"Influenza","enrollment":153},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT03497845","phase":"PHASE2","title":"Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2018-03-15","conditions":"Influenza A Virus, H5N1 Subtype","enrollment":720},{"nctId":"NCT01788228","phase":"PHASE3","title":"Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-22","conditions":"Influenza, Influenza Vaccines","enrollment":50},{"nctId":"NCT02587221","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-30","conditions":"Influenza","enrollment":6790},{"nctId":"NCT02768805","phase":"PHASE2","title":"Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-03-02","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":900},{"nctId":"NCT03283319","phase":"PHASE2","title":"Panblok H7 Vaccine Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2017-09-20","conditions":"Influenza, Human","enrollment":366},{"nctId":"NCT00449670","phase":"PHASE3","title":"Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-24","conditions":"Influenza, Influenza Vaccines","enrollment":1206},{"nctId":"NCT03701061","phase":"PHASE4","title":"Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-10-11","conditions":"Influenza A Subtype H5N1 Infection","enrollment":12},{"nctId":"NCT01178918","phase":"","title":"Non-specific Response to H1N1 Vaccine","status":"COMPLETED","sponsor":"The University Clinic of Pulmonary and Allergic Diseases Golnik","startDate":"2009-11","conditions":"Influenza H1N1","enrollment":14},{"nctId":"NCT00971906","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":660},{"nctId":"NCT00306995","phase":"PHASE2","title":"Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-11","conditions":"Influenza, Influenza Vaccines","enrollment":385},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT00868218","phase":"PHASE1","title":"Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Rebecca Cox","startDate":"2009-03","conditions":"Influenza, Healthy","enrollment":60},{"nctId":"NCT02236052","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population","status":"COMPLETED","sponsor":"Medicago","startDate":"2014-07-16","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Influenza vaccine, adjuvanted","genericName":"Influenza vaccine, adjuvanted","companyName":"Arcturus Therapeutics, Inc.","companyId":"arcturus-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"An adjuvanted influenza vaccine that enhances immune response through the addition of an adjuvant to improve antibody production and cellular immunity against influenza virus strains. Used for Influenza prevention in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}